Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Stock Short Interest Rises 1,421.2%

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) saw a large growth in short interest in the month of September. As of September 30th, there was short interest totaling 89,977 shares, a growth of 1,421.2% from the September 15th total of 5,915 shares. Currently, 6.1% of the shares of the company are short sold. Based on an average daily trading volume, of 32,888 shares, the days-to-cover ratio is presently 2.7 days.

Global X Genomics & Biotechnology ETF Stock Performance

Global X Genomics & Biotechnology ETF stock traded up $2.92 during trading hours on Friday, reaching $68.75. 24,290 shares of the stock were exchanged, compared to its average volume of 20,312. Global X Genomics & Biotechnology ETF has a 52-week low of $40.17 and a 52-week high of $74.19. The stock has a market cap of $101.75 million, a P/E ratio of -29.38 and a beta of 1.17. The firm’s 50 day moving average is $64.48 and its 200 day moving average is $54.66.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in GNOM. Farther Finance Advisors LLC acquired a new stake in Global X Genomics & Biotechnology ETF in the third quarter valued at about $257,000. Wealth Management Partners LLC purchased a new stake in Global X Genomics & Biotechnology ETF in the 1st quarter valued at approximately $244,000. Polaris Financial Partners acquired a new position in Global X Genomics & Biotechnology ETF during the 3rd quarter worth approximately $1,067,000. Finally, Bank of America Corp DE increased its position in Global X Genomics & Biotechnology ETF by 67.8% during the 1st quarter. Bank of America Corp DE now owns 119,795 shares of the company’s stock worth $5,240,000 after purchasing an additional 48,394 shares during the period. 56.95% of the stock is owned by hedge funds and other institutional investors.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.